Literature DB >> 14723481

Guideline development for office-based pharmacotherapies for opioid dependence.

David A Fiellin1, Andrea G Barthwell.   

Abstract

The success of opioid agonist maintenance has stimulated efforts to make this form of treatment more available. Methadone medical maintenance, coordination of methadone services from a physician's office, has been offered as an alternative to narcotic treatment programs for stable, recovered and socially rehabilitated opioid dependent patients. Despite the successful implementation of methadone medical maintenance programs, a number of important questions regarding the appropriate guidelines for the use of this model of care remain. The current paper reviews the process and outcome of the Medical Maintenance Consensus Panel, which was convened for the federal Center for Substance Abuse Treatment. We outline the process and describe the two guidelines that were produced by this process that are targeted at physicians, narcotic treatment programs, and policy makers.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14723481     DOI: 10.1300/j069v22n04_09

Source DB:  PubMed          Journal:  J Addict Dis        ISSN: 1055-0887


  8 in total

1.  Buprenorphine retention in primary care.

Authors:  Michael D Stein; Patricia Cioe; Peter D Friedmann
Journal:  J Gen Intern Med       Date:  2005-11       Impact factor: 5.128

2.  Adoption of practice guidelines and assessment tools in substance abuse treatment.

Authors:  Traci Rieckmann; Bret E Fuller; Goal Auzeen Saedi; Dennis McCarty
Journal:  Subst Abuse Treat Prev Policy       Date:  2010-03-26

3.  Antidepressant treatment does not improve buprenorphine retention among opioid-dependent persons.

Authors:  Michael D Stein; Debra S Herman; Malyna Kettavong; Patricia A Cioe; Peter D Friedmann; Tahir Tellioglu; Bradley J Anderson
Journal:  J Subst Abuse Treat       Date:  2010-07-03

4.  A 5-year evaluation of a methadone medical maintenance program.

Authors:  Kenneth A Harris; Julia H Arnsten; Herman Joseph; Joe Hecht; Ira Marion; Patti Juliana; Marc N Gourevitch
Journal:  J Subst Abuse Treat       Date:  2006-09-07

5.  The Physician Clinical Support System-Buprenorphine (PCSS-B): a novel project to expand/improve buprenorphine treatment.

Authors:  James E Egan; Paul Casadonte; Tracy Gartenmann; Judith Martin; Elinore F McCance-Katz; Julie Netherland; John A Renner; Linda Weiss; Andrew J Saxon; David A Fiellin
Journal:  J Gen Intern Med       Date:  2010-05-11       Impact factor: 5.128

6.  Factors affecting willingness to provide buprenorphine treatment.

Authors:  Julie Netherland; Michael Botsko; James E Egan; Andrew J Saxon; Chinazo O Cunningham; Ruth Finkelstein; Mark N Gourevitch; John A Renner; Nancy Sohler; Lynn E Sullivan; Linda Weiss; David A Fiellin
Journal:  J Subst Abuse Treat       Date:  2008-08-20

7.  A pilot study of a distress tolerance treatment for opiate-dependent patients initiating buprenorphine: rationale, methodology, and outcomes.

Authors:  Richard A Brown; Erika Litvin Bloom; Jacki Hecht; Ethan Moitra; Debra S Herman; Michael D Stein
Journal:  Behav Modif       Date:  2014-06-27

Review 8.  Primary care models for treating opioid use disorders: What actually works? A systematic review.

Authors:  Pooja Lagisetty; Katarzyna Klasa; Christopher Bush; Michele Heisler; Vineet Chopra; Amy Bohnert
Journal:  PLoS One       Date:  2017-10-17       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.